St. Jude Kicks Off Heart Plug Trial
St. Jude Medicalannounced on Friday that it has enrolled the first patient in its trial to judge the effectiveness of its Amplatzer Cardiac Plug in preventing stroke in patients suffering from atrial fibrillation. The trial, dubbed the ACP Trial, will measure both efficacy and safety of the device, while enrolling between 400 and 3,000 patients in the U.S. and Canada.
The American Heart Association estimates 2.7 million Americans suffer from atrial fibrillation, making the market a potentially lucrative one for St. Jude. The World Health Organization further projects around a third of all atrial fibrillation patients will suffer a stroke in their lifetimes if not treated.
The Amplatzer Cardiac Plug first won CE Mark approval in 2008, and St. Jude is hoping successful data from the ACP Trial can contribute to an FDA approval, as well.
St. Jude's President of Medical Cardiovascular and Ablation Technologies Division, Frank J Callaghan, explained the opportunity provided by the trial, saying:
The AMPLATZER Cardiac Plug has shown great promise in international markets and we look forward to establishing the evidence required to make it available in the U.S.... This trial will help us understand the long-term benefits of LAA occlusion therapy for lowering the risk of stroke in atrial fibrillation patients and potentially improve their quality of life.
St. Jude shares rose 1.3% on Friday with the announcement.
The article St. Jude Kicks Off Heart Plug Trial originally appeared on Fool.com.Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.